Coronavirus Vaccine / IAVI, Batavia Biosci - LARVOL DELTA

Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2. (PubMed, J Exp Med) - "The S2 subunit of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is highly conserved across coronavirus strains and therefore is a potential pan-coronavirus vaccine target. The antibodies targeted two different sites: one defined by competition with stem helix antibodies, and the second to an underdescribed epitope at the apex of S2. These findings suggest that S2-targeted vaccines could strategically exploit controlled OC43 priming followed by SARS-CoV-2 boosting to enhance the breadth and quality of protective antibody responses."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift. (PubMed, Cell Rep) - "Developing broad coronavirus vaccines hinges on identifying and understanding the molecular basis of conserved spike epitopes targeted by broadly neutralizing antibodies (bnAbs)...Notably, site V remains largely unchanged across SARS-CoV-2 variants and is conserved among diverse sarbecoviruses, highlighting its potential as a broad vaccine target. Our findings underscore the need for targeted vaccine strategies to induce immunofocused B cell responses to escape resistant subdominant spike RBD bnAb epitopes."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes. (PubMed, Cell Rep) - "We also report CC24.2, a pan-sarbecovirus neutralizing antibody that targets a unique receptor-binding domain (RBD) epitope and shows similar neutralization potency against all tested SARS-CoV-2 variants, including BQ.1.1 and XBB.1.5. A cocktail of TXG-0078 and CC24.2 shows protection in vivo, suggesting their potential use in variant-resistant therapeutic Ab cocktails and as templates for pan-coronavirus vaccine design."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Enabling the evaluation of COVID-19 vaccines with correlates of protection. (PubMed, Biologicals) - "CoPs for broadly protective beta-coronavirus vaccines remain a critical area of research. The knowledge, expertise, and capacity exist to conduct clinical studies using different designs in different populations to discover and validate CoPs, facilitating and accelerating evaluation of novel vaccines/vaccination platforms."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2. (PubMed, Cell Rep) - "Vaccines remain successful at limiting severe disease and death, but the potential for further coronavirus zoonosis motivates the search for pan-coronavirus vaccines...Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density. The S2 domain may therefore provide a more attractive target for immunogen design efforts aiming to generate a pan-coronavirus antibody response."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. (PubMed, Immunity) - "Structural studies of these bnAbs delineated the molecular basis for their broad reactivity and revealed common antibody features targetable by broad vaccination strategies. These bnAbs provide new insights and opportunities for antibody-based interventions and for developing pan-betacoronavirus vaccines."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases